Mirum Pharmaceuticals Inc. (MIRM), which reported global net product sales growth of 137% in the first quarter of 2024, is progressing steadily towards achieving its annual growth objective of 66% to 72%.
The company has three approved medications - Livmarli oral solution, Cholbam capsules, and Chenodal tablets.
-- Livmarli is indicated for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) 3 months of age and older, and progressive familial intrahepatic cholestasis five years of age and older in the U.S. The drug is also approved by the European Commission for the treatment of cholestatic pruritus in patients with ALGS two months and older, and by Health Canada for the treatment of cholestatic pruritus in ALGS.
For comments and feedback contact: editorial@rttnews.com
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.